Brian Armstrong wants to cure aging. And investors are writing very large checks to let him try.
NewLimit, the San Francisco-based biotech company co-founded by the Coinbase CEO, just closed a $435 million funding round that values the company at $3.1 billion in post-money terms. That’s roughly triple its previous valuation, which sat below $1 billion as recently as its Series B last year.
From crypto fortunes to cellular rejuvenation
Armstrong is best known for building Coinbase into one of the largest crypto exchanges on the planet. But since 2022, he’s been quietly building something in an entirely different domain: a company that wants to make human cells young again.
He co-founded NewLimit alongside Blake Byers and Jacob Kimmel, the latter a former scientist at Calico, Alphabet’s longevity research lab. The premise is deceptively simple. As we age, our cells lose the ability to express genes the way they did when we were younger. NewLimit’s bet is that you can flip those switches back on.
